Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 148 of the 148 references it cites were found in a registry or an index; 41 of the 84 sources its claims cite were checked for support.

Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility

Open access
Cobelli, Claudio, Kovatchev, Boris · 2023 · Journal of Diabetes Science and Technology

Abstract

Arguably, diabetes mellitus is one of the best quantified human conditions. In the past 50 years, the metabolic monitoring technologies progressed from occasional assessment of average glycemia via HbA1c, through episodic blood glucose readings, to continuous glucose monitoring (CGM) producing data points every few minutes. Mathematial models and computer simulation of the human metabolic system became indispensable for the technological progress of diabetes treatment, enabling every step, from assessment of insulin sensitivity via the now classic Minimal Model of Glucose Kinetics, to in silico trials replacing animal experiments, to automated insulin delivery algorithms. In 2007, we introduced a sophisticated model of glucose-insulin dynamics and a computer simulator equipped with a population of N = 300 in silico subjects with type 1 diabetes. In January 2008, the Food and Drug Administration (FDA) accepted this simulator as a substitute to animal trials for the pre-clinical testing of new treatment approaches.

Overview

CoChat Summary

TL;DR

This review traces the development of the UVA/Padova type 1 diabetes simulator from the Minimal Model to an FDA-accepted in silico population of 300 subjects, and its role in enabling automated insulin delivery. It argues that in silico preclinical testing has largely replaced animal trials for artificial pancreas algorithm development and has contributed to clinically deployed systems such as Control-IQ.

Key findings

  • The 2007 simulator included N = 300 in silico T1D “subjects”: N = 100 children below age 11, N = 100 adolescents 12–18 years, and N = 100 adults; in January 2008 the FDA accepted it as a substitute for animal trials for preclinical testing of insulin treatments and closed-loop algorithms (Device Master File 1521).
  • A 24-hour period of closed-loop control can be simulated in under 2 seconds, but the authors state that good in silico performance does not guarantee in vivo performance and is only a prerequisite to, not a substitute for, clinical trials.
  • Refinements added functionality including diurnal insulin sensitivity, dawn phenomenon, glucagon effects, a GLP-1 model, extension from single meal to single day, acetaminophen pharmacokinetics, long-acting insulin, intraperitoneal insulin absorption, replay simulation, and insulin sensitivity assessment; an IP simulator was used in an in silico study of 100 adults and to design a PID controller for IP insulin delivery without meal announcement.
  • Legacy: the first wearable AID system, Diabetes Assistant (DiAs), was developed in 2011; Control-IQ was FDA-authorized in 2019 as the “first interoperable, automated insulin dosing controller,” is cleared in over 25 countries, and has over 400,000 users; real-life data from 9,300 users for a year and 21,000 users for four months confirmed performance virtually identical to pivotal trials. A PubMed search found about 555 papers on closed-loop control or AID algorithms since 1979, and by 2023 six proposed algorithms advanced to clinical practice.

Methods

  • Narrative review following the development of mathematical models and computer simulation for diabetes treatment, from the Minimal Model of Glucose Kinetics to the UVA/Padova T1D simulator.
  • Draws on prior physiological data, including triple tracer mixed meal studies in >200 adults and children, and describes the creation of an in silico population whose parameters cover key in vivo parameter distributions.
  • Synthesizes simulator validation, refinements, and utility, including a sample of 30 publications spanning 12 years and a PubMed search of approximately 555 papers; no new primary data or formal meta-analysis are reported.

Limitations

  • Stated limitations: Not stated in the paper.
  • Evident from the text: this is a narrative review by the simulator’s developers, not a systematic review; the authors state they include only a sample of 30 publications and that it is not possible to review all uses of the simulation environment.
  • Evident from the text: the authors declare potential conflicts of interest, including research support, patent royalties, and honoraria from diabetes technology companies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1177/19322968231195081

Cites

148 of 148 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

21 Valid · 6 Not valid · 23 Not checked · 21 Own results and interpretations

27 more claims · 6 with their cited sources checked

Create a free account to see all 71 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 25
  • It may state two separate claims as one. 23
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 145 references

Research works printed but not linked: 3

  1. Pickup JC, Williams G. Textbook of Diabetes 2. Hoboken, NJ: Blackwell Publishing, 2003.
  2. Shichiri M, Kawamori R, Yamasaki Y, Inoue M, Shigeta Y, Abe H. Computer algorithm for the artificial pancreatic beta cell. Artif Organs. 1978;2(suppl):247-250.
  3. 10.2337/dc20-225. · doi:10.2337/dc20-225

Cited by

See all 46

Metadata

Authors
Cobelli, C., & Kovatchev, B.
Affiliations
  • University of Padua (IT)
  • University of Virginia (US)
Corresponding author
Cobelli, Claudio
Venue
Journal of Diabetes Science and Technology
Published
2023-09-25
Volume
17
Issue
6
Pages
1493-1505
ISSN
1932-2968 (ISSN-L)
OpenAlex
W4387002681
Cited by
46
References
145
Citations by year
2026: 23 · 2025: 16 · 2024: 7
FWCI
9.37
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Diabetes Science and Technology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases (RO1 DK 133148)
  • European Commission Horizon 2020 (FORGETDIABETES-FET-EU951933)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
type 1 diabetes, UVA/Padova simulator, in silico modeling, glucose-insulin dynamics, continuous glucose monitoring, artificial pancreas, in silico clinical trials, population simulation
MeSH terms
Algorithms, Blood Glucose, Computer Simulation, Diabetes Mellitus, Type 1, Glucose, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Blood Glucose Self-Monitoring, Pancreas, Artificial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility. https://app.cochat.ai/papers/10.1177/19322968231195081
The paper
Cobelli, C., & Kovatchev, B. (2023). Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility. Journal of Diabetes Science and Technology. https://doi.org/10.1177/19322968231195081

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.